This License Agreement (this "Agreement") is made effective as of the 6th day of September, 1994 between
CORTISOL MEDICAL RESEARCH, INC. (CMR), of Las Vegas, Nevada, a Nevada Corporation and
STEROIDEGENESIS INHIBITORS, INC., a Nevada Corporation.
HERETO, the parties agree as follows:
GRANT OF LICENSE
In consideration of 5,100,000 shares of STEROIDEGENESIS INHIBITORS, INC. Common Stock, a 3-5%
licensing fees on ANTICORT net sales (on a sliding scale), and $250,000 to be paid, if and when
STEROIDEGENESIS INHIBITORS, INC. would successfully conclude a private/IPO financing of 5MM or
more, CORTISOL MEDICAL RESEARCH, INC. grants to STEROIDEGENESIS INHIBITORS, INC.
exclusive, world wide license to ANTICORT, an anti-AIDS drug, developed by CMR, together with all
technology, and the know-how related to the use of ANTICORT.
STEROIDEGENESIS INHIBITORS, INC., at its own expense, shall file and pursue patent(s) application(s) on
ANTICORT, which said patent(s) to be issued in DR. ALFRED T. SAPSE'S name, but to be used by
STEROIDEGENESIS INHIBITORS, INC. for the duration of said patents, or seventeen years after the
issuance of the patents.
TRANSFER OF RIGHTS
This Agreement shall be binding on any successors of the parties.
This Agreement contains the entire agreement of the parties and there are no other promises or conditions in any
other agreement whether oral or written. This Agreement supersedes any prior written or oral agreements
between the parties.
This Agreement may be modified or amended, if the amendment is made in writing and is signed by both parties.
If any provision of this Agreement shall be held to be invalid or unenforceable for any reason, the remaining
provisions shall continue to be valid and enforceable. If a court finds that any provision of this Agreement is
invalid or unenforceable, but that by limiting such provision it would become valid or enforceable, then such
provision shall be deemed